Sarkaria, Jann N.

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 7,575

A role for ATR in the DNA damage-induced phosphorylation of p53

Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., & Abraham, R. T. (1999) · Genes & Development

DNA Repair MechanismsCancer-related Molecular Pathways

Cited by 1,046

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology

Barrier Structure and Function StudiesGlioma Diagnosis and Treatment

Cited by 746

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

Chan, K.-M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C. D., Jenkins, R., et al. (2013) · Genes & Development

Glioma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 707

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response

Sarkaria, J. N., Carlson, B. L., Schroeder, M. A., Grogan, P., Brown, P. D., Giannini, C., Ballman, K. V., Kitange, G. J., Guha, A., Pandita, A., et al. (2006) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

Cited by 270

Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery

Carlson, B. L., Pokorny, J. L., Schroeder, M. A., & Sarkaria, J. N. (2011) · Current Protocols in Pharmacology

Glioma Diagnosis and TreatmentCancer Cells and Metastasis

Cited by 227

Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma

Vaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 227

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts

Kitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research

Glioma Diagnosis and TreatmentEpigenetics and DNA Methylation

Cited by 151

Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data

Abdelmoula, W. M., Regan, M. S., Lopez, B. G. C., Randall, E. C., Lawler, S., Mladek, A. C., Nowicki, M. O., Marin, B. M., Agar, J. N., Swanson, K. R., et al. (2019) · Analytical Chemistry

Mass Spectrometry Techniques and ApplicationsMedical Image Segmentation Techniques

Cited by 62

Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist

Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 49

Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor

Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., et al. (2020) · Scientific Reports

Cancer, Hypoxia, and MetabolismGlioma Diagnosis and Treatment

Cited by 45

Hypoxia-inducible factor 2α: a novel target in gliomas

Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018) · Future Medicinal Chemistry

Cancer, Hypoxia, and MetabolismGlioma Diagnosis and Treatment

Cited by 40

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

Kim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentBarrier Structure and Function Studies

Cited by 39

MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation

Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines

Cancer-related Molecular PathwaysGlioma Diagnosis and Treatment

Cited by 30

How much is enough? Impact of efflux transporters on drug delivery leading to efficacy in the treatment of brain tumors

Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2023) · Pharmaceutical Research

Drug Transport and Resistance MechanismsBarrier Structure and Function Studies

Cited by 19

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 8

Abstract 3870: The addition of CB-839 to temozolomide significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model

Kizilbash, S. H., Burgenske, D. M., McBrayer, S., Devarajan, S., Gupta, S. K., Hitosugi, T., He, L., Schroeder, M. A., Carlson, B. L., Gelman, M., et al. (2019) · Cancer Research

Glioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

Cited by 4

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)

Sarkaria, J. N., Mrugala, M. M., Jaeckle, K. A., Burns, T. C., Vaubel, R. A., Parney, I. F., Chaichana, K., Clement, P. M., Martinez-Garcia, M., Sepulveda Sanchez, J. M., et al. (2024) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 3

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 2

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 0